Company Overview and News

 
GlaxoSmithKline Pharmaceuticals Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
GlaxoSmithKline Pharmaceuticals Limited - Trading Window

2018-03-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
GSK puts Horlicks under review, hints at sale of Indian consumer biz to fund $13 bn Novartis buy

2018-03-27 moneycontrol
British drug giant GSK on Tuesday said it has put its popular nutritional health brand Horlicks under "strategic review" to fund the USD 13 billion acquisition of Novartis consumer health business.

 
GlaxoSmithKline Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-03-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
GlaxoSmithKline Pharmaceuticals Limited - Cessation

2018-03-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
GlaxoSmithKline Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-03-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
PNB to move out of Nifty Midcap 100 index

2018-02-21 moneycontrol
The scam-hit Punjab National Bank (PNB) will move out of the NSE's Nifty Midcap 100 index from April.

 
Despite big fall, most fundamentallystrong stocks still remain expensive

2018-02-05 thehindubusinessline
Priya Kansara If you thought that you could buy your favourite stocks after the carnage on Friday wherein Nifty Midcap and Nifty Smallcap had tanked 4 per cent and 6 per cent, respectively, on a single trading session, then here is the bad news. Most stocks, which lost the most on Black Friday, have not been among analysts’ top picks. So, investors have no choice but to keep a long-term view and buy the good stocks or future likely outperformers at expensive valuation.

 
GlaxoSmithKline Pharma Q3 profit up 69% at Rs89 crore

2018-02-02 livemint
New Delhi: Drug firm GlaxoSmithKline Pharmaceuticals on Friday reported a 69.38% rise in its standalone net profit to Rs89.69 crore for the quarter ended December 2017.

 
GlaxoSmithKline Pharmaceuticals Limited - Press Release

2018-02-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
GlaxoSmithKline Pharmaceuticals Limited - Financial Result Updates

2018-02-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
WNS Holdings' (WNS) CEO Keshav Murugesh on Q3 2018 Results - Earnings Call Transcript

2018-01-18 seekingalpha
Good morning, and welcome to the WNS Holdings’ Fiscal 2018 Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After management’s prepared remarks, we will conduct a question-and-answer session, and instructions for how to ask a question will follow at that time. As a reminder, this conference call is being recorded for replay purposes.

 
GlaxoSmithKline Pharmaceuticals Limited - Trading Window

2017-12-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...